ANIMAL HEALTH PARTNERSHIP
BIOASTER and DA VOLTERRA signed a memorandum of understanding to initiate a research partnership based on the novel economic model of Technology Research Institute (TRIs).
The project, entitled DACCAR, (Destroy Antibiotics in Colon to Combat Antibiotic Resistance), aims to develop an innovative product limiting the emergence of multi-resistant bacteria in patients treated with antibiotics to protect the intestinal microbial flora from antibiotics side effects.
Thus, using a DACCAR product would result in minimizing nosocomial infections burden maintaining effectiveness of antibiotics (noteworthy carbapenems) reducing spread of antibiotic resistance.
Partnership with a leading Animal Health Company
In May 2012, Da Volterra entered into a Collaborative Agreement with a leading Animal Health Company to develop its product DAV133 in veterinary applications. DAV133 targets monogastric animals (such as pigs, veals, canines and felines...) with the objective to decrease the rise and dissemination of resistant bacteria linked to antibiotic treatments in companion animals and livestock. This agreement represents a major step for Da Volterra towards the market access of one of its products in animal health. Under this agreement, the two partners are involved in synergy in the product development efforts, Da Volterra being responsible for the product optimization and preclinical studies, and the Animal Health Company taking charge of the regulatory, pre-marketing, and final-development steps.
Led by Da Volterra, the NOSOBIO project is dedicated to the fight against nosocomial infections. It has received the support of Oséo (ISI program). It aims to develop solutions for the prevention of bacterial resistance to antibiotics, and for diagnostic of patients screening colonized by multi-resistant bacteria at their entrance in the hospital and the identification of new antibiotics.
In Nosobio, Da Volterra’s is pooling its efforts with AP-HP, Institut Pasteur and Genewave to obtain the initial proof-of-concept of its products that have been recognized as breakthrough innovations in the management of resistant infections and especially the prevention of resistant nosocomial infections.
The overall purpose of EvoTAR (Evolution and Transfer of Antibiotic Resistance) is to increase the understanding of the evolution and spread of antibiotic resistance in human pathogens. EvoTAR aims to characterise the human reservoir of antibiotic resistance genes (“the resistome”) by investigating the interaction between resistant and non-resistant bacteria from the human microbiome and the interrelations of the human resistome with environmental, animal and food reservoirs of resistance genes.
Within EvoTAR, Da Volterra has the unique opportunity to partner with several scientific leaders investigating the complexity of the microbiota with powerful metagenomics approaches. Prof. Dusko Ehrlich from INRA will apply top-notched metagenomics techniques, developed in the MetaHIT European program, to study the evolution of the flora when submitted to antibiotic treatments with and without the DAV132 product.
EvoTAR is a 4-year project (2011-2015) with a budget of €12 millions. It brings together 17 partners, mostly academic, coming from 7 different countries : Da Volterra, The University Medical Center Utrecht (UMCU), Wageningen University (WU), Instituto Biomar, The University of Copenhagen (UCPH), The Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Universidad Complutense de Madrid (UCM), The Agencia Estatal Consejo Superior de Investigaciones Científicas (CSIC), University of Paris Diderot Medical school, the Institut National de la Recherche Agronomique (INRA), The University of Edinburgh, Uppsala University, the University of Siena, the University of Cantabria, The Technical University of Denmark (DTU), The Institut Pasteur and Microdish.
EvoTAR is a program co-funded by the European Commission in the context of the 7th Framework Programme.
R-GNOSIS (Resistance in Gram-Negative Organisms: Studying Intervention Strategies) is a European collaborative initiative determining – in the most relevant patient populations – the efficacy and effectiveness of cutting-edge interventions to reduce carriage, infection and spread of Multi-Drug resistant Gram-negative Bacteria (MDR-GNB).
R-GNOSIS has received funding from the European Community's 7th Framework Programme. In this project, Da Volterra is partnering with 4 highly-renowned European clinical centers to pursue the development of its products. The expertise of the associated clinicians in leading trials and managing resistant infections is a clear
R-GNOSIS will last 5 years (2011-2016) and gathers 20 partners coming from 9 different European countries.
TRAIN-ASAP (Training and Research Aimed at Novel Antibacterial Solutions in Animals and People) is a Marie Curie Initial Training Network funded under the 7th Framework Programme of the European Commission. The project is dedicated to the scientific and professional training of 14 early-stage researchers with the aim to develop novel antibacterial solutions for humans and animals. The consortium includes 9 academic institutions, 8 private enterprises and 2 national research centres representing 10 countries.
The global objective of the ENDETECH (ENzymatic Decontamination TECHnology) program is to develop a technology which aims at eliminating persistent pharmaceutical pollutants in wastewaters originating from drug manufacturing sites, households, hospitals and animal farms, thanks to an innovative ENzymatic Decontamination TECHnology. The pharmaceutical pollutants targeted in priority during this project will be antibiotics and hormones & endocrine disruptors.
Da Volterra, leader of this 3-year project is working closely with 5 other partners originate from 4 different countries: c-LEcta and the Goethe Frankfurt University (Germany), ChiralVision (The Netherlands), the European Membrane Institute from the CNRS (France) and the Catalan Institute for Water Research (Spain).